|
|
|
|
pmid:
|
Khot A et al. |
Development of a Translational Physiologically Based Pharmacokinetic Model for Antibody-Drug Conjugates: a Case Study with T-DM1. |
2017 |
AAPS J |
pmid:28808917
|
Bender B et al. |
A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer. |
2014 |
AAPS J |
pmid:24917179
|
Ait-Oudhia S et al. |
A Mechanism-Based PK/PD Model for Hematological Toxicities Induced by Antibody-Drug Conjugates. |
2017 |
AAPS J |
pmid:28646408
|
Loebrich S et al. |
Development and Characterization of a Neutralizing Anti-idiotype Antibody Against Mirvetuximab for Analysis of Clinical Samples. |
2017 |
AAPS J |
pmid:28534292
|
Singh AP and Shah DK |
Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1). |
2017 |
AAPS J |
pmid:28374319
|
Erickson HK and Lambert JM |
ADME of antibody-maytansinoid conjugates. |
2012 |
AAPS J |
pmid:22875610
|
Cilliers C et al. |
Multiscale Modeling of Antibody-Drug Conjugates: Connecting Tissue and Cellular Distribution to Whole Animal Pharmacokinetics and Potential Implications for Efficacy. |
2016 |
AAPS J |
pmid:27287046
|
Singh AP et al. |
Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1). |
2016 |
AAPS J |
pmid:27029797
|
Maass KF et al. |
Determination of Cellular Processing Rates for a Trastuzumab-Maytansinoid Antibody-Drug Conjugate (ADC) Highlights Key Parameters for ADC Design. |
2016 |
AAPS J |
pmid:26912181
|
Chari RV |
Targeted cancer therapy: conferring specificity to cytotoxic drugs. |
2008 |
Acc. Chem. Res. |
pmid:17705444
|
Kim SU et al. |
Neurofibrillary degeneration in cultured adult mouse neurons induced by maytansine. |
1980 |
Acta Neuropathol. |
pmid:7435167
|
Kolarich AR et al. |
Ado-trastuzamab emtansine associated hyponatremia and intracranial hemorrhage. |
2014 |
Acta Oncol |
pmid:24834794
|
Dymowski W and Furmanowa M |
[Investigating cytostatic substances in tissue of plants Maytenus Molina in in-vitro cultures. II. chromatographic test of extracts from callus of Maytenus wallichiana R. et B]. |
1990 |
Acta Pol Pharm |
pmid:1669332
|
Lambert JM and Morris CQ |
Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review. |
2017 |
Adv Ther |
pmid:28361465
|
Friedkin M and Rozengurt E |
The role of cytoplasmic microtubules in the regulation of the activity of peptide growth factors. |
1980 |
Adv. Enzyme Regul. |
pmid:7039258
|
Patel KC et al. |
Ado-trastuzumab emtansine for the treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer. |
2014 |
Am J Health Syst Pharm |
pmid:24644113
|
Traynor K |
Ado-trastuzumab emtansine approved for advanced breast cancer. |
2013 |
Am J Health Syst Pharm |
pmid:23515502
|
Muzaffar M et al. |
Acute Pancreatitis Associated With Ado-Trastuzumab Emtansine. |
|
Am J Ther |
pmid:25756468
|
Esteva FJ et al. |
What Can We Learn about Antibody-Drug Conjugates from the T-DM1 Experience? |
2015 |
Am Soc Clin Oncol Educ Book |
pmid:25993162
|
Stinchcombe TE |
Novel formulations and new mechanisms of delivering chemotherapy. |
2014 |
Am Soc Clin Oncol Educ Book |
pmid:24857128
|
Martin M and López-Tarruella S |
Emerging Therapeutic Options for HER2-Positive Breast Cancer. |
2016 |
Am Soc Clin Oncol Educ Book |
pmid:27249772
|
Thigpen JT et al. |
Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary. A Gynecologic Oncology Group study. |
1983 |
Am. J. Clin. Oncol. |
pmid:6846245
|
Thigpen JT et al. |
Phase II study of maytansine in the treatment of advanced or recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group study. |
1983 |
Am. J. Clin. Oncol. |
pmid:6869315
|
Borden EC et al. |
Phase II evaluation of dibromodulcitol, ICRF-159, and maytansine for sarcomas. |
1982 |
Am. J. Clin. Oncol. |
pmid:6956236
|
Slavik M et al. |
Phase II studies in advanced, recurrent pelvic malignancies: conducted by the Gynecologic Oncology Group, Experimental Design and Experience. |
1982 |
Am. J. Clin. Oncol. |
pmid:6897490
|
Ravry MJ et al. |
Phase II evaluation of maytansine (NSC 153858) in advanced cancer. A Southeastern Cancer Study Group trial. |
1985 |
Am. J. Clin. Oncol. |
pmid:3834790
|
Fleming MS et al. |
A reversed-phase high-performance liquid chromatography method for analysis of monoclonal antibody-maytansinoid immunoconjugates. |
2005 |
Anal. Biochem. |
pmid:15840500
|
Luo Q et al. |
Structural Characterization of a Monoclonal Antibody-Maytansinoid Immunoconjugate. |
2016 |
Anal. Chem. |
pmid:26629796
|
Sang H et al. |
Conjugation site analysis of antibody-drug-conjugates (ADCs) by signature ion fingerprinting and normalized area quantitation approach using nano-liquid chromatography coupled to high resolution mass spectrometry. |
2017 |
Anal. Chim. Acta |
pmid:28088282
|
Eichner S et al. |
The interplay between mutasynthesis and semisynthesis: generation and evaluation of an ansamitocin library. |
2012 |
Angew. Chem. Int. Ed. Engl. |
pmid:22135226
|
Monneret C |
[Current impact of natural products in the discovery of anticancer drugs]. |
2010 |
Ann Pharm Fr |
pmid:20637355
|
Corrigan PA et al. |
Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate. |
2014 |
Ann Pharmacother |
pmid:25082874
|
Leal M et al. |
Antibody-drug conjugates: an emerging modality for the treatment of cancer. |
2014 |
Ann. N. Y. Acad. Sci. |
pmid:25123209
|
Luduena RF et al. |
Interactions of vinblastine and maytansine with tubulin. |
1986 |
Ann. N. Y. Acad. Sci. |
pmid:3460446
|
Krop IE et al. |
Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. |
2015 |
Ann. Oncol. |
pmid:25355722
|
Martin M et al. |
Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. |
2016 |
Ann. Oncol. |
pmid:27052654
|
Gebhart G et al. |
Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. |
2016 |
Ann. Oncol. |
pmid:26598545
|
Foglietta J et al. |
Letter to the editor concerning 'Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA'. |
2015 |
Ann. Oncol. |
pmid:25632067
|
Olson EM et al. |
Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. |
2012 |
Ann. Oncol. |
pmid:21531783
|
Sibaud V et al. |
T-DM1-related telangiectasias: a potential role in secondary bleeding events. |
2015 |
Ann. Oncol. |
pmid:25403586
|
Gradishar WJ |
Emerging approaches for treating HER2-positive metastatic breast cancer beyond trastuzumab. |
2013 |
Ann. Oncol. |
pmid:23827380
|
Wall ME and Wani MC |
Antineoplastic agents from plants. |
1977 |
Annu. Rev. Pharmacol. Toxicol. |
pmid:326159
|
Maslin DN |
[Ansamycins]. |
1979 |
Antibiotiki |
pmid:37801
|
Mescher C et al. |
Left Ventricular Ejection Fraction Screening and Clinical Decision-making in Metastatic HER2-positive Breast Cancer. |
2017 |
Anticancer Res. |
pmid:28668870
|
Michel LL et al. |
T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. |
2015 |
Anticancer Res. |
pmid:26254411
|
Tanida S et al. |
Inhibition of cilia regeneration of Tetrahymena by ansamitocins, new antitumor antibiotics. |
1979 |
Antimicrob. Agents Chemother. |
pmid:475367
|
Hanka LJ and Barnett MS |
Microbiological assays and bioautography of maytansine and its homologues. |
1974 |
Antimicrob. Agents Chemother. |
pmid:15825322
|
Zhao M et al. |
Effects of the Methylmalonyl-CoA Metabolic Pathway on Ansamitocin Production in Actinosynnema pretiosum. |
2017 |
Appl. Biochem. Biotechnol. |
pmid:27787765
|
Li T et al. |
Improvement of ansamitocin P-3 production by Actinosynnema mirum with fructose as the sole carbon source. |
2015 |
Appl. Biochem. Biotechnol. |
pmid:25564203
|